PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Programmed death-1 (PD-1) is a crucial T cell checkpoint receptor.
• Its ligand, programmed death-ligand 1 (PD-L1), inhibits T cell activation upon binding.
• Elevated PD-L1 expression in tumors facilitates immune escape.

Purpose of the Study:

• To review the structure and function of the PD-1/PD-L1 signaling pathway.
• To discuss the application of anti-PD-1/PD-L1 antibodies in cancer immunotherapy.
• To explore future directions and combination therapies.

Main Methods:

• Literature review of PD-1 and PD-L1 structure and function.
• Analysis of PD-1/PD-L1 signaling pathways.
• Review of current and emerging anti-PD-1/PD-L1 antibody therapies.

Main Results:

• Detailed review of PD-1 and PD-L1 molecular structures.
• Explanation of the inhibitory signaling cascade mediated by PD-1/PD-L1.
• Overview of therapeutic applications of monoclonal antibodies targeting PD-1/PD-L1.

Conclusions:

• The PD-1/PD-L1 pathway is a significant target for cancer immunotherapy.
• Anti-PD-1/PD-L1 antibodies represent a rapidly developing therapeutic strategy.
• Combination therapies hold potential for enhanced efficacy and future curative treatments.